LGVN

Longeveron LLC

LGVN, USA

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

https://longeveron.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
LGVN
stock
LGVN

Portfolio Recap: Can LGVN deliver alpha - Weekly Trade Analysis & Smart Investment Allocation Insights baoquankhu1.vn

Read more →
LGVN
stock
LGVN

Aug Action: Can LGVN continue delivering strong returns - Weekly Risk Summary & Advanced Technical Signal Analysis baoquankhu1.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$6.8625

Analyst Picks

Strong Buy

0

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.15

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-72.46 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-46.42 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-3,731.39 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

High

0.56

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 4.61% of the total shares of Longeveron LLC

1.

Vanguard Group Inc

(0.6937%)

since

2025/06/30

2.

Geode Capital Management, LLC

(0.6804%)

since

2025/06/30

3.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4766%)

since

2025/07/31

4.

Citadel Advisors Llc

(0.4503%)

since

2025/06/30

5.

UBS Group AG

(0.4046%)

since

2025/06/30

6.

Fidelity Extended Market Index

(0.3492%)

since

2025/07/31

7.

XTX Topco Ltd

(0.2308%)

since

2025/06/30

8.

State Street Corp

(0.2182%)

since

2025/06/30

10.

Commonwealth Equity Services Inc

(0.121%)

since

2025/06/30

11.

Fidelity Total Market Index

(0.1157%)

since

2025/07/31

12.

Fidelity Series Total Market Index

(0.0981%)

since

2025/07/31

13.

Northern Trust Corp

(0.0764%)

since

2025/06/30

14.

NT Ext Equity Mkt Idx Fd - L

(0.0732%)

since

2025/06/30

15.

Northern Trust Extended Eq Market Idx

(0.0732%)

since

2025/06/30

16.

Spartan Extended Market Index Pool F

(0.0686%)

since

2025/07/31

17.

Lido Advisors, LLC

(0.054%)

since

2025/06/30

18.

BlackRock Inc

(0.0482%)

since

2025/06/30

19.

Bank of Montreal

(0.0481%)

since

2025/06/30

20.

BMO Capital Markets Corp.

(0.0481%)

since

2025/06/30

21.

Spartan Total Market Index Pool G

(0.0347%)

since

2025/07/31

22.

Tower Research Capital LLC

(0.0247%)

since

2025/06/30

23.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0207%)

since

2025/06/30

24.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0174%)

since

2024/12/31

25.

Fidelity Nasdaq Composite Index

(0.0141%)

since

2025/07/31

26.

Steward Partners Investment Advisory, LLC

(0.0114%)

since

2025/06/30

27.

Advisor Group Holdings, Inc.

(0.0096%)

since

2025/06/30

28.

Extended Equity Market Fund K

(0.007%)

since

2025/06/30

29.

Morgan Stanley - Brokerage Accounts

(0.0033%)

since

2025/06/30

30.

NT Ext Equity Mkt Idx Fd - NL

(0.0029%)

since

2025/06/30

31.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0023%)

since

2025/06/30

32.

Extended Equity Market Fund M

(0.0009%)

since

2025/06/30

33.

Bank of America Corp

(0.0006%)

since

2025/06/30

34.

Hanson Mcclain Inc

(0.0006%)

since

2025/06/30

35.

State St US Extended Mkt Indx NL Cl C

(0.0006%)

since

2025/08/31

36.

State St US Ttl Mkt Indx NL Cl A

(0.0003%)

since

2025/08/31

37.

SBI Securities Co Ltd

(0.0002%)

since

2025/06/30

38.

SSgA U.S. Total Market Index Strategy

(0.0002%)

since

2025/03/31

39.

Northern Trust Wilshire 5000

(0.0002%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.39

EPS Estimate

-0.26

EPS Difference

-0.13

Surprise Percent

-50%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1)
Momentum
Strong Momentum(6.5)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(2)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.